Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-001 DDI Study with Metformin, Midazolam, and Clarithromycin
NCT06227832Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of serabelisib in vascular malformations (VM) (3 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Area under the concentration-time curve from time 0 extrapolated to infinite time at 11 days and Maximum observed concentration at 11 days. Started Dec 2023; status: completed.
02
Drugs
serabelisib
03
Conditions
vascular malformations (VM)
Beyond the preview
Go deeper on NCT06227832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227832.